DARTS Sciences offers (1) unbiased proteome-wide drug target identification using state-of-the-art proteomics and mass spectrometry technologies, (2) specified protein target binding assays for your drug of interest, and (3) drug screening against “undruggable” therapeutic targets. Currently, the high failure rate in drug development continues to be an enormous burden to the pharmaceutical industry and society. DARTS Sciences’ patented Drug Affinity Responsive Target Stability (DARTS) technology provides drug target identification and validation services to the pharmaceutical industry and academic/nonprofit researchers. DARTS is advantageous because it can be performed using lysates from any cell or tissue type.

Graduated in 2018